188 related articles for article (PubMed ID: 31862860)
41. Opioids for the management of breakthrough pain in cancer patients.
Zeppetella G; Davies AN
Cochrane Database Syst Rev; 2013 Oct; (10):CD004311. PubMed ID: 24142465
[TBL] [Abstract][Full Text] [Related]
42. A network meta-analysis of the efficacy of opioid analgesics for the management of breakthrough cancer pain episodes.
Zeppetella G; Davies A; Eijgelshoven I; Jansen JP
J Pain Symptom Manage; 2014 Apr; 47(4):772-785.e5. PubMed ID: 23981487
[TBL] [Abstract][Full Text] [Related]
43. Intranasal fentanyl spray: a novel dosage form for the treatment of breakthrough cancer pain.
Dietrich E; Gums JG
Ann Pharmacother; 2012 Oct; 46(10):1382-91. PubMed ID: 23012382
[TBL] [Abstract][Full Text] [Related]
44. Breakthrough cancer pain treatment in Spain: physicians' perception of current opioids utilization and prescription.
Villegas Estévez F; López Alarcón MD; Alonso Babarro A; Olay Gayoso L; de Castro J; Lería-Gelabert M; Melogno-Klinkas M
Curr Med Res Opin; 2020 Aug; 36(8):1383-1391. PubMed ID: 32453602
[No Abstract] [Full Text] [Related]
45. Lack of correlation between the effective dose of fentanyl sublingual spray for breakthrough cancer pain and the around-the-clock opioid dose.
Nalamachu SR; Parikh N; Dillaha L; Rauck R
J Opioid Manag; 2014; 10(4):247-54. PubMed ID: 25162604
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and safety of sublingual fentanyl orally disintegrating tablets in patients with breakthrough pain: multicentre prospective study.
Guitart J; Vargas I; De Sanctis V; Ferreras J; Fuentes J; Salazar R; Vázquez JM; Folch J; Moya J; Ribera H; Rodelas F; Tomás A; Arilla M; Coma J; Aberasturi T; Sintes D; Lombán E
Clin Drug Investig; 2013 Sep; 33(9):675-83. PubMed ID: 23881567
[TBL] [Abstract][Full Text] [Related]
47. Breakthrough pain and its treatment: critical review and recommendations of IOPS (Italian Oncologic Pain Survey) expert group.
Mercadante S; Marchetti P; Cuomo A; Mammucari M; Caraceni A;
Support Care Cancer; 2016 Feb; 24(2):961-968. PubMed ID: 26438145
[TBL] [Abstract][Full Text] [Related]
48. Fentanyl sublingual spray for breakthrough cancer pain in patients receiving transdermal fentanyl.
Alberts DS; Smith CC; Parikh N; Rauck RL
Pain Manag; 2016 Oct; 6(5):427-34. PubMed ID: 27020837
[TBL] [Abstract][Full Text] [Related]
49. Low-dose sublingual fentanyl improves quality of life in patients with breakthrough cancer pain in palliative care.
Rodríguez AT; Viejo MN; Maradey P; Canal-Sotelo J; Mancilla PG; Rivero SG; Casillas IR; Abián MH; Bermudo CL
Future Oncol; 2022 May; 18(14):1717-1731. PubMed ID: 35137627
[TBL] [Abstract][Full Text] [Related]
50. A randomized, double-blind, placebo-controlled study of fentanyl buccal tablets for breakthrough pain: efficacy and safety in Japanese cancer patients.
Kosugi T; Hamada S; Takigawa C; Shinozaki K; Kunikane H; Goto F; Tanda S; Shima Y; Yomiya K; Matoba M; Adachi I; Yoshimoto T; Eguchi K
J Pain Symptom Manage; 2014 Jun; 47(6):990-1000. PubMed ID: 24099893
[TBL] [Abstract][Full Text] [Related]
51. Impact of individualized management of breakthrough cancer pain on quality of life in advanced cancer patients: CAVIDIOPAL study.
Tuca Rodríguez A; Núñez Viejo M; Maradey P; Canal-Sotelo J; Guardia Mancilla P; Gutiérrez Rivero S; Raja Casillas I; Herrera Abián M; López Bermudo C
Support Care Cancer; 2021 Aug; 29(8):4799-4807. PubMed ID: 33533986
[TBL] [Abstract][Full Text] [Related]
52. Managing breakthrough pain.
Mercadante S
Curr Pain Headache Rep; 2011 Aug; 15(4):244-9. PubMed ID: 21424673
[TBL] [Abstract][Full Text] [Related]
53. Knowledge and practice of the management of breakthrough cancer pain among general practitioners providing palliative care in Shanghai, China: a cross-sectional survey.
Yu Y; Zhang P; Chen D; Jiang SF
BMJ Open; 2023 Sep; 13(9):e073670. PubMed ID: 37770268
[TBL] [Abstract][Full Text] [Related]
54. Breakthrough Cancer Pain: A Systematic Review of Pharmacologic Management
.
Brant JM; Rodgers BB; Gallagher E; Sundaramurthi T
Clin J Oncol Nurs; 2017 Jun; 21(3 Suppl):71-80. PubMed ID: 28524907
[TBL] [Abstract][Full Text] [Related]
55. Breakthrough pain management using fentanyl buccal tablet (FBT) in combination with around-the-clock (ATC) opioids based on the efficacy and safety of FBT, and its relationship with ATC opioids: results from an open-label, multi-center study in Japanese cancer patients with detailed evaluation.
Takigawa C; Goto F; Tanda S; Shima Y; Yomiya K; Matoba M; Adachi I; Yoshimoto T; Eguchi K
Jpn J Clin Oncol; 2015 Jan; 45(1):67-74. PubMed ID: 25381384
[TBL] [Abstract][Full Text] [Related]
56. Breakthrough cancer pain (BTcP) management: a review of international and national guidelines.
Davies AN; Elsner F; Filbet MJ; Porta-Sales J; Ripamonti C; Santini D; Webber K
BMJ Support Palliat Care; 2018 Sep; 8(3):241-249. PubMed ID: 29875184
[TBL] [Abstract][Full Text] [Related]
57. Prevalence and characterization of breakthrough pain in cancer patients with proctalgia treated with 3D pelvic radiotherapy.
Ferrero VT; Oset MM; Masferrer JP; Pardo EH; Sorolla EJ; Largo SC;
Clin Transl Oncol; 2019 Dec; 21(12):1707-1711. PubMed ID: 30949931
[TBL] [Abstract][Full Text] [Related]
58. A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain.
Portenoy RK; Burton AW; Gabrail N; Taylor D;
Pain; 2010 Dec; 151(3):617-624. PubMed ID: 20800358
[TBL] [Abstract][Full Text] [Related]
59. Analyzing Differences in Perception between Oncologists and Patients to Adapt Pharmacological Treatment for Breakthrough Cancer Pain: Observational ADAPTATE Study.
Cabezón-Gutiérrez L; Álamo-González C; Monge-Martín D; Caballero-Martínez F
J Palliat Med; 2022 Jun; 25(6):925-931. PubMed ID: 35049361
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
